Brief: Jw (Cayman) Therapeutics Says NMPA Accepted Biological License Application For Carteyva
04/01/2024 15:30
Jan 4 (Reuters) - JW (Cayman) Therapeutics Co Ltd
2126.HK :
* NMPA ACCEPTED SUPPLEMENTAL BIOLOGICAL LICENSE APPLICATION
FOR
CARTEYVA
Further company coverage: 2126.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on JW (Cayman) Therapeutics Co
See all newsChina pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says
Brief: JW (Cayman) Therapeutics Appoints Tian Feng As CEO, Executive Director
Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment
Brief: JW (Cayman) Therapeutics H1 Net Income RMB -267.3 Million
Brief: JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License